Compare KLA Corp. (KLAC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Smith & Nephew plc — how do they compare? KLA Corp. trades at $208.17 (market cap $272.09B), while Smith & Nephew plc trades at $30.14 (market cap $12.38B). The key difference: KLA Corp. is far larger — about 22× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| KLAC | SNN | |
|---|---|---|
Market Cap | $272.09B | $12.38B |
Sector | Technology | Health |
52-Week High | $301.71 | $38.70 |
52-Week Low | $84.39 | $28.73 |
Enterprise Value | $273.34B | $15.41B |
Dividend Yield | 0.44% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $209.37, up 4.44% today, with a bullish technical signal and strong support near $206. Recent earnings beats and a 63.63% analyst buy rating reflect robust fundamentals, including a 35.57% net margin and 87.5% ROE. The stock split and dividend hikes signal confidence, while AI-driven semiconductor demand supports growth.
Outlook is positive with a $246.93 consensus price target, though high valuation ratios (P/E 56.9) and sector volatility pose risks. Revenue growth to $13.6B in 2026 and operational cash flow strength underpin opportunities, but investors should monitor margin pressures and cyclical chip demand.
SNN trades at $30.11, up 0.33% today, with a bearish technical signal but improving fundamentals. Recent earnings show mixed results, beating in Q4 2025 and Q2 2026 but missing earlier quarters. Revenue growth has accelerated from $5.2B in 2022 to $6.16B in 2025, with net income margin expanding to 10.08%. The company maintains a dividend, with the next payment scheduled for November 2026. News highlights include product launches in robotics and wound care, though Q2 2026 revenue growth fell short of expectations.
Outlook is cautiously optimistic due to solid profitability and innovation, but risks include U.S. market softness and competitive pressures. Analysts largely recommend Hold, reflecting balanced growth potential against execution challenges. The stock's valuation at a P/E of 20.3 appears reasonable if earnings momentum continues, but investors should monitor operational execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
